微流控阻抗红细胞检测在镰状细胞病中的应用
研究用微流控阻抗红细胞检测(MIRCA)分析68例成人和34例儿童镰状细胞病患者的红细胞变形能力,发现常氧阻塞指数(NOI)和低氧阻塞指数(HOI)升高与炎症、溶血、红细胞密度、年龄及严重基因型正相关,NOI每升高1%与每年急性并发症发生率升高6.3%相关。
要点
- MIRCA可机械测量红细胞变形能力,输出常氧阻塞指数(NOI)和低氧阻塞指数(HOI)。
- NOI和HOI升高与炎症、溶血、红细胞密度、年龄及严重镰状细胞病基因型正相关。
- 个体NOI每升高1%,每年急性并发症发生率升高6.3%。
核心结论
- MIRCA可与临床实验室检查联合用于常规门诊监测红细胞变形能力作为临床状态生物标志物,并可纳入疾病修饰药物临床试验。
研究设计与样本
- 研究分析了68例成年和34例儿童镰状细胞病患者红细胞,使用微流控阻抗红细胞检测(MIRCA)测量变形能力。
- MIRCA提供常氧阻塞指数(NOI)和低氧阻塞指数(HOI)作为读数。
主要发现
- 较高的HOI和NOI值与炎症标志物、溶血、红细胞密度、较大年龄及严重镰状细胞病基因型(纯合HbSS或HbS β0-地中海贫血)正相关。
- 个体NOI每升高1%,每年急性并发症发生率升高6.3%。
- 过去一年有慢性并发症的个体NOI中位数比无慢性并发症者高3.1%。
- 接受慢性输血治疗的个体存在MIRCA可捕获而商用设备LoRRca未捕获的变形不良红细胞亚群。
- 体外向慢性输血治疗个体样本中加入voxelotor或osivelotor可改善这些内源性红细胞的变形能力。
临床怎么用
- MIRCA可与临床实验室检查联合用于常规门诊就诊时监测红细胞变形能力作为临床状态生物标志物。
- MIRCA可纳入疾病修饰药物的临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In sickle cell disease (SCD), red blood cells (RBCs) are poorly deformable, even under normoxia (NOI). With deoxygenation, deformability of sickle RBCs is further reduced due to polymerization of hemoglobin S (HbS). Rigid, poorly deformable sickle RBCs block microvasculature, causing ischemia, pain, and organ damage. The microfluidic impedance red cell assay (MIRCA) can mechanically measure RBC deformability, providing occlusion index under NOI or hypoxia (HOI) as readouts. We analyzed RBCs from 68 adult and 34 pediatric patients with SCD using the MIRCA. Higher HOI and NOI values were positively associated with markers of inflammation, hemolysis, RBC density, older age, and severe SCD genotypes (homozygous HbSS or HbS β0-thalassemia. Each 1% higher NOI across individuals was associated with a 6.3% higher incidence of acute complications per year. Individuals with chronic complications in the past year had a 3.1% higher median NOI than those without chronic complications. Individuals on chronic transfusion therapy exhibit a subpopulation of poorly deformable RBCs captured by the MIRCA but not by a commercially available device that also measures RBC deformability, the laser assisted optical rotational cell analyzer (LoRRca). In vitro addition of voxelotor or osivelotor to samples from individuals on chronic transfusion therapy improved the deformability of these endogenous RBCs. Longitudinally collected NOI and HOI values in individuals with HbSS were stable, with a median percent point change of 13.3% and 15.7%, respectively. MIRCA can be used in combination with clinical laboratory tests to monitor RBC deformability as a biomarker of clinical status at routine clinic visits and included in clinical trials of disease-modifying agents.
引用
- Patwardhan AA, Patel A, Pasupuleti A, et al. Use of the microfluidic impedance red cell assay in sickle cell disease. Blood Adv. 2025. PMID: 40311069. doi:10.1182/bloodadvances.2024015590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。